Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2013
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Alfa Wassermann Inc
- 30 Mar 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 12 Oct 2011 New trial record